| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 544233000 | Polycyclo ring system having a 1,2-diazine ring as one of the cyclos | 33 |
| 20150073145 | MODULAR SYNTHESIS OF GRAPHENE NANORIBBONS AND GRAPHENE SUBSTRUCTURES FROM OLIGO-ALKYNES - A method for the synthesis of carbon-based structures, particularly graphene substructures and ribbons, from oligo- and poly-alkyne starting materials. | 03-12-2015 |
| 544234000 | Tricyclo ring system having the 1,2-diazine ring as one of the cyclos | 1 |
| 20110196153 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES - Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds. | 08-11-2011 |
| 544235000 | Bicyclo ring system having the 1,2-diazine ring as one of the cyclos | 31 |
| 20100137590 | N[S(4-ARYL-TRIAZOL-3-YL)alpha-MERCAPTOACETYL] -P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS - A series of S-triazolyl α-mercaptoacetanilides having N-(α-mercaptoacetyl) p amino benzoic acid derivatives. | 06-03-2010 |
| 20110144331 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders - This invention relates to novel compounds having the structural formula I below: | 06-16-2011 |
| 20130217878 | (AZA)INDOLIZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF - (Aza)indolizine derivatives represented by Formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In Formula (I), 0 to 2 of X | 08-22-2013 |
| 544236000 | At least three ring nitrogens in the bicyclo ring system | 17 |
| 20090018335 | FUSED HETEROCYCLIC COMPOUND - The present invention relates to a compound represented by the formula: | 01-15-2009 |
| 20090023920 | IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INTERMEDIATES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS AND PESTICIDES - The invention relates to new substituted imidazoles of general formula | 01-22-2009 |
| 20090247748 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND - A process for producing a sulfonyl chloride compound comprising: | 10-01-2009 |
| 20090306374 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF - The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. | 12-10-2009 |
| 20100137591 | PROCESS FOR PREPARING 3-METHYL-4-PHENYLISOXAZOLO [3,4-D]PYRIDAZIN-7(6H)-ONE - A process for preparing 3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one which process comprises the steps of: (a) reacting 1-phenylbutane-1,3-dione with ethyl 2-chloro-2-(hydroxyimino)actetate; and (b) subsequently reacting the product from step (a) with hydrazine or an hydrate thereof to yield 3-methyl-4-phenylisoxazolo-[3,4-d]pyridin-7(6H)-one, wherein step (b) is carried out on the mixture resulting from step (a) without isolating ethyl 4-benzoyl-5-methylisoxazole-3-carboxylate therefrom. | 06-03-2010 |
| 20100168424 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF - The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof | 07-01-2010 |
| 20100197912 | Polymorphic and hydrate forms, salts and process for preparing 6-quinoline - The invention relates to novel polymorphic and hydrate forms and salts of 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline, to methods for their preparation, to pharmaceutical compositions comprising at least one of said polymorphic or hydrate forms or salts, and to the therapeutic and/or prophylactic use of such compositions. The invention also provides new manners for preparing said compound. | 08-05-2010 |
| 20100234597 | PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND - A process for producing an imidazo[1,2-b]pyridazine compound represented by the formula (2): | 09-16-2010 |
| 20110098471 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING - The present invention provides a novel antimicrobial drug comprising an oxazolidinone derivative of the formula (I): | 04-28-2011 |
| 20120302748 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer. | 11-29-2012 |
| 20130178622 | Methods and Compositions for Treating Cancer - The invention features methods, kits, and pharmaceutical compositions for treating cancer using 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)-methyl)-3-(trifluoromethyl)phenyl)benzamide. | 07-11-2013 |
| 20130296557 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS - The present invention relates to novel diarylacetylene hydrazide compounds of formula (I) or pharmaceutically acceptable salt thereof, as tyrosine kinase inhibitors, the process for their preparation, and to the use of the compounds of formula (I) in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to tyrosine kinases, in warm-blooded animals | 11-07-2013 |
| 20130345424 | COMPOSITIONS AND USES THEREOF TO AMELIORATE PAIN - Hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, compositions comprising hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, and methods for using them for the treatment of pain are described. | 12-26-2013 |
| 20140343282 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF - Novel synthetic approaches to make 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof are provided. | 11-20-2014 |
| 20150112061 | COMPOSITIONS AND USES THEREOF TO AMELIORATE PAIN - Hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, compositions comprising hydrazinopyridazines, fused hydrazinopyridazines, phenyl ethylhydrazines, or combinations thereof, and methods for using them for the treatment of pain are described. | 04-23-2015 |
| 20150322069 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS - Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof. | 11-12-2015 |
| 20160108053 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF - Novel synthetic approaches to make 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof are provided. | 04-21-2016 |
| 544237000 | Phthalazines (including hydrogenated) | 11 |
| 20090187018 | Manufacture of Pure Hydralazine Salts - The present invention provides an improved process of preparing hydralazine hydrochloride, which involves the preparation of 1-chlorophthalazine salt and further reacting with hydrazine followed by purification of hydralazine hydrochloride, which is free of phosphate, does not contain any individual impurities more than 0.05%, total impurities less than 0.5%, and a hydrazine content of not more than 0.001 %, and preferably less than 0.0003%. One benefit of improved purity is enhanced storage stability. | 07-23-2009 |
| 20090270617 | PHTHALAZINONE DERIVATIVE - 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A. | 10-29-2009 |
| 20100222584 | PHARMACEUTICAL GRADE PHTHALAZINEDIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention comprises methods of manufacturing a highly purified, pharmaceutical grade phthalazinedione for administration to a human or animal. The manufacturing methods identify and isolate starting materials, and prepare intermediate products, which are suitable for the commercial batch process production of highly purified and high-yielding intermediate products and final phthalazinedione products. | 09-02-2010 |
| 20110015393 | PHTHALAZINONE COMPOUND - 4-(4-Fluoro-3-(4-methoxypiperidine-1-carbonyl)benzyl)phthalazin-1(2H)-one as crystalline Form C. | 01-20-2011 |
| 20110054171 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINES - Salts of optically active [4-(2-diphenylphosphanylnaphthalen-1-yl)phthalazin-1-yl]-(1-phenylethyl)amines represented by the formulas (1) to (4) with an optically active organic sulfonic acid, and a production method thereof. | 03-03-2011 |
| 20110301347 | BENZYL, AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS - The present invention relates to the compounds of formula I, | 12-08-2011 |
| 20120101272 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate. | 04-26-2012 |
| 20120316337 | METHOD FOR PREPARING CHEMICAL COMPOUNDS OF INTEREST BY NUCLEOPHILIC AROMATIC SUBSTITUTION OF AROMATIC CARBOXYLIC ACID DERIVATIVES SUPPORTING AT LEAST ONE ELECTRO-ATTRACTIVE GROUP - Method for preparing carboxylic acid derivatives by aromatic nucleophilic substitution, in which a carboxylic acid derivative having a single carboxyl functional group, or one of the salts thereof, the carboxylic acid derivative having, in the ortho position of the carboxyl functional group, a leaving group, which is preferably an atom of fluorine or of chlorine or an alkoxy group, chiral or not, preferably a methoxy group, the carboxylic acid derivative not being substituted by an electro attractive group other than the leaving group if any; is reacted with a reactant MNu, where M is a metal and Nu is a nucleophile, chiral or not, the aromatic nucleophilic substitution reaction being carried out without a catalyst and without a step of protecting/deprotecting the acid functional group of the starting compound. | 12-13-2012 |
| 20140235857 | INTERMEDIATE FOR MANUFACTURE OF POLYMERIZABLE COMPOUND AND PROCESS FOR MANUFACTURE THEREOF - The present invention pertains to a compound represented by a formula (I) and a method for producing thereof (in the formula, A | 08-21-2014 |
| 20140323725 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES - Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds. | 10-30-2014 |
| 20170233351 | Process for the Preparation of Olaparib and Intermediates Thereof | 08-17-2017 |
